Johnson & Johnson

News

J&J claims first approval for PARP combo Akeega

Johnson & Johnson has picked up its first regulatory approval worldwide for Akeega, a fixed-dose combination of a PARP inhibitor and anti-androgen therapy, as a treatm

News

NICE says yes to J&J, AbbVie first-line leukaemia regimen

Patients in England with chronic lymphocytic leukaemia (CLL) will be able to access a new combination therapy based on Johnson & Johnson’s Imbruvica plus AbbVie’s Venc

News

Leaked data shows stellar efficacy for J&J’s Carvykti

Johnson & Johnson was preparing to divulge the data from its eagerly-awaited CARTITUDE-4 trial of CAR-T therapy Carvykti later this year, but a leak of the data has gi

News

Litigation costs pour cold water on J&J’s finances

Johnson & Johnson posted a loss in the first three months of the year as it booked a massive $6.9 billion charge related to its recently-agreed proposal to settle clai

News

J&J raises talc offer to $9bn with new insolvency bid

Johnson & Johnson has made an offer of nearly $9 billion to try to resolve tens of thousands of lawsuits it faces in the US that claim its talc products cause cancer.&

News

J&J’s bankruptcy bid to resolve talc claims blocked

Johnson & Johnson’s attempt to draw a line under the ongoing litigation it faces over allegations that its talc products cause cancer has been blocked by an appeals co

J&J claims first approval for PARP combo Akeega

NICE says yes to J&J, AbbVie first-line leukaemia regimen

Leaked data shows stellar efficacy for J&J’s Carvykti

Litigation costs pour cold water on J&J’s finances

J&J raises talc offer to $9bn with new insolvency bid

J&J’s bankruptcy bid to resolve talc claims blocked

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Johnson & Johnson

Editor's Picks